The ARDS, Pneumonia, and Sepsis (APS) Consortium is funded through a collaboration between the National Heart, Lung, and Blood Institute and NIGMS. This large observational study will collect longitudinal data and biospecimens from approximately 4,000 adults hospitalized with acute respiratory distress syndrome (ARDS), pneumonia, or sepsis at over 20 hospitals in the United States. The scientific goal is to conduct analyses to gain greater understanding of the biological mechanisms underlying APS and, in particular, to link to well-defined clinical phenotypes.

We’ve issued a new notice: NIGMS Support to Utilize Data and Biospecimens Generated by the ARDS, Pneumonia, and Sepsis (APS) Phenotyping Consortium (NOT-GM-24-018). The purpose is to inform investigators that we’ll support studies that fall within the NIGMS mission and utilize biospecimens or data generated from the APS Consortium.

We want the research community to know about two funding opportunity announcements (FOAs) that NIGMS has joined as part of an NHLBI initiative to support the formation of a multisite study, the Acute Respiratory Distress Syndrome (ARDS), Pneumonia, and Sepsis Phenotyping (APS) Consortium. The study seeks to better define the heterogeneity underlying critical illness syndromes and to identify the mechanisms of illness development and recovery, as well as relationships and overlap between these syndromes. The FOAs are: